|
WO1984000560A1
(en)
|
1982-08-04 |
1984-02-16 |
Nat Res Dev |
Molecular cloning of the gene for human anti-haemophilic factor ix
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5049386A
(en)
|
1985-01-07 |
1991-09-17 |
Syntex (U.S.A.) Inc. |
N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4946787A
(en)
|
1985-01-07 |
1990-08-07 |
Syntex (U.S.A.) Inc. |
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
WO1986006408A1
(en)
|
1985-04-22 |
1986-11-06 |
Genetics Institute, Inc. |
HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
|
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
FR2638643B1
(fr)
|
1988-11-09 |
1991-04-12 |
Transgene Sa |
Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
ATE515510T1
(de)
|
1991-12-24 |
2011-07-15 |
Isis Pharmaceuticals Inc |
Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
KR960702518A
(ko)
|
1993-05-17 |
1996-04-27 |
린다 에스, 스티븐슨 |
Hiv 감염 및 aids에 대한 리보자임 유전자 치료(ribozyme gene therapy for hiv infection and aids)
|
|
CA2186118C
(en)
|
1994-03-23 |
2010-10-19 |
Richard W. Hanson |
Compacted nucleic acids and their delivery to cells
|
|
GB9408717D0
(en)
|
1994-05-03 |
1994-06-22 |
Biotech & Biolog Scien Res |
DNA sequences
|
|
EP0760008A1
(en)
|
1994-05-19 |
1997-03-05 |
Dako A/S |
Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
|
|
ES2355588T3
(es)
|
1997-03-14 |
2011-03-29 |
The Children's Hospital Of Philadelphia |
Composiciones para uso en terapia génica para el tratamiento de hemofilia.
|
|
WO1998054345A1
(en)
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
|
WO1999003496A1
(en)
|
1997-07-21 |
1999-01-28 |
The University Of North Carolina At Chapel Hill |
Factor ix antihemophilic factor with increased clotting activity
|
|
EP1626091B1
(en)
|
2000-06-01 |
2014-07-23 |
University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
US7465583B2
(en)
|
2000-06-01 |
2008-12-16 |
The University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
US20030143740A1
(en)
|
2001-10-15 |
2003-07-31 |
Christine Wooddell |
Processes for transposase mediated integration into mammalian cells
|
|
US20030108524A1
(en)
|
2001-10-18 |
2003-06-12 |
Melissa Diagana |
Vectors for expressing multiple transgenes
|
|
DK2359869T3
(en)
|
2001-12-17 |
2019-04-15 |
Univ Pennsylvania |
Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
|
|
ES2420929T3
(es)
|
2002-07-18 |
2013-08-27 |
Monsanto Technology Llc |
Procedimientos de utilización de polinucleótidos artificiales y sus composiciones para reducir el silenciamiento de transgenes
|
|
US7579176B2
(en)
|
2003-10-15 |
2009-08-25 |
Newlight Technologies, Llc |
Method for the production of polyhydroxyalkanoic acid
|
|
ES2436741T3
(es)
|
2004-09-22 |
2014-01-07 |
St. Jude Children's Research Hospital |
Expresión mejorada de Factor IX en vectores de terapia génica
|
|
US7951925B2
(en)
|
2006-05-25 |
2011-05-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
|
EP2423307A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IV polypeptides and use thereof for treatment
|
|
CN101511373B
(zh)
|
2006-06-19 |
2015-12-09 |
阿斯克肋匹奥生物制药公司 |
用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
|
|
US8110379B2
(en)
|
2007-04-26 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Targeted integration into the PPP1R12C locus
|
|
CA2720903C
(en)
|
2008-04-14 |
2019-01-15 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
JP5908725B2
(ja)
|
2008-08-22 |
2016-04-26 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
標的一本鎖開裂および標的組込みのための方法、並びに組成物
|
|
ES2985035T3
(es)
|
2008-09-15 |
2024-11-04 |
Uniqure Biopharma B V |
Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
|
|
EP3156494B8
(en)
|
2008-12-04 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
AU2010235161B2
(en)
|
2009-04-09 |
2015-01-22 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
KR20120097483A
(ko)
|
2009-07-24 |
2012-09-04 |
시그마-알드리치 컴퍼니., 엘엘씨 |
게놈 편집을 위한 방법
|
|
EA201290069A1
(ru)
|
2009-07-31 |
2012-07-30 |
Байер Хелскер Ллс |
Модифицированные полипептиды фактора ix и их применения
|
|
JP6137596B2
(ja)
|
2010-02-08 |
2017-05-31 |
サンガモ セラピューティクス， インコーポレイテッド |
遺伝子操作された切断ハーフドメイン
|
|
US9255259B2
(en)
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
WO2011146885A2
(en)
|
2010-05-21 |
2011-11-24 |
Virxsys Corporation |
Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing
|
|
US9057057B2
(en)
|
2010-07-27 |
2015-06-16 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
|
EP2627665B1
(en)
|
2010-10-12 |
2015-12-16 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia B
|
|
ES2685611T3
(es)
|
2011-02-14 |
2018-10-10 |
The Children's Hospital Of Philadelphia |
Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
|
|
EP2758529B1
(en)
|
2011-09-21 |
2019-03-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
|
US9222105B2
(en)
|
2011-10-27 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
JP6342886B2
(ja)
|
2012-04-18 |
2018-06-13 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ |
Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
|
|
DK2839013T3
(da)
|
2012-04-18 |
2020-09-14 |
Univ Leland Stanford Junior |
Ikke-disruptiv-gen-targetering
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
|
EP4397759A3
(en)
|
2012-10-23 |
2024-10-09 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
CA2892448A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
DK3363902T3
(da)
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
US10227610B2
(en)
|
2013-02-25 |
2019-03-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
ES2887254T3
(es)
|
2013-03-08 |
2021-12-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
|
US10604771B2
(en)
|
2013-05-10 |
2020-03-31 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP2997146A4
(en)
*
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
SG11201510327TA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
CA3229275A1
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
|
CN105813814B
(zh)
|
2013-12-12 |
2017-09-12 |
3M创新有限公司 |
制备聚合物多层膜的方法
|
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
EP3110454B1
(en)
|
2014-02-24 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
WO2015200555A2
(en)
|
2014-06-25 |
2015-12-30 |
Caribou Biosciences, Inc. |
Rna modification to engineer cas9 activity
|
|
EP3169776B1
(en)
|
2014-07-14 |
2025-09-03 |
The Regents of The University of California |
Crispr/cas transcriptional modulation
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
CN113337533A
(zh)
|
2014-12-23 |
2021-09-03 |
先正达参股股份有限公司 |
用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
|
|
AU2016226077B2
(en)
|
2015-03-03 |
2021-12-23 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases with altered PAM specificity
|
|
JP6851319B2
(ja)
|
2015-04-27 |
2021-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
EP4378487A3
(en)
|
2015-06-23 |
2024-09-04 |
The Children's Hospital of Philadelphia |
Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
US11279928B2
(en)
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3159407A1
(en)
|
2015-10-23 |
2017-04-26 |
Silence Therapeutics (London) Ltd |
Guide rnas, methods and uses
|
|
US10143760B2
(en)
|
2015-10-28 |
2018-12-04 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
|
US11866727B2
(en)
*
|
2015-11-06 |
2024-01-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1A
|
|
CN106893739A
(zh)
|
2015-11-17 |
2017-06-27 |
香港中文大学 |
用于靶向基因操作的新方法和系统
|
|
EP3380622A4
(en)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
|
|
WO2017093804A2
(en)
*
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
EP3392337B1
(en)
|
2015-12-18 |
2024-03-06 |
Japan Science and Technology Agency |
Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes
|
|
EP3402533B1
(en)
|
2016-01-15 |
2021-08-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
US11083799B2
(en)
|
2016-03-16 |
2021-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
|
ES3030658T3
(en)
|
2016-03-30 |
2025-07-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle formulations for crispr/cas components
|
|
CA3026110A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN105950626B
(zh)
|
2016-06-17 |
2018-09-28 |
新疆畜牧科学院生物技术研究所 |
基于CRISPR/Cas9获得不同毛色绵羊的方法及靶向ASIP基因的sgRNA
|
|
CA3030587A1
(en)
|
2016-07-15 |
2018-01-18 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
JP7256739B2
(ja)
|
2016-09-07 |
2023-04-12 |
サンガモ セラピューティクス， インコーポレイテッド |
肝臓遺伝子のモジュレーション
|
|
WO2018058064A1
(en)
|
2016-09-23 |
2018-03-29 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing
|
|
KR102712926B1
(ko)
|
2016-10-20 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
파브리병의 치료를 위한 방법 및 조성물
|
|
EP3551757A1
(en)
|
2016-12-08 |
2019-10-16 |
Intellia Therapeutics, Inc. |
Modified guide rnas
|
|
US20180185516A1
(en)
|
2016-12-09 |
2018-07-05 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
JP7383478B2
(ja)
|
2016-12-22 |
2023-11-20 |
インテリア セラピューティクス，インコーポレイテッド |
アルファ１アンチトリプシン欠乏症を治療するための組成物および方法
|
|
US11597947B2
(en)
|
2016-12-29 |
2023-03-07 |
Asc Therapeutics Inc. |
Gene editing method using virus
|
|
US11938197B2
(en)
|
2017-01-10 |
2024-03-26 |
The Sydney Children's Hospitals Network (Randwick And Westmead (Incorporating The Royal Alexandra Hospital For Children) |
Polynucleotides and vectors for the expression of transgenes
|
|
JP7215716B2
(ja)
|
2017-01-13 |
2023-01-31 |
学校法人自治医科大学 |
肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのａａｖベクター
|
|
IL268110B2
(en)
|
2017-01-26 |
2024-01-01 |
Sangamo Therapeutics Inc |
B-cell engineering
|
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
JP2020519272A
(ja)
|
2017-05-09 |
2020-07-02 |
エモリー ユニバーシティー |
凝固因子変異体及びその使用
|
|
TWI753168B
(zh)
|
2017-05-22 |
2022-01-21 |
日商武田藥品工業股份有限公司 |
用於血友病ｂ基因療法之編碼具有增強表現的重組ｆｉｘ變異體之病毒載體
|
|
US11667934B2
(en)
|
2017-06-15 |
2023-06-06 |
Toolgen Incorporated |
Platform for expressing protein of interest in liver
|
|
CN111032867A
(zh)
|
2017-06-16 |
2020-04-17 |
应用干细胞有限公司 |
具有提高的敲入效率的基因编辑方法
|
|
GB2566453B
(en)
|
2017-09-12 |
2021-01-13 |
Univ Of Northumbria At Newcastle |
Impactor for aerosol component collection
|
|
EP3688162B1
(en)
|
2017-09-29 |
2024-03-06 |
Intellia Therapeutics, Inc. |
Formulations
|
|
IL311278B2
(en)
|
2017-09-29 |
2026-05-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing
|
|
US20220080055A9
(en)
|
2017-10-17 |
2022-03-17 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
|
EP3714055A1
(en)
*
|
2017-11-21 |
2020-09-30 |
CRISPR Therapeutics AG |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
US11891635B2
(en)
|
2017-12-21 |
2024-02-06 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Nucleic acid sequence replacement by NHEJ
|
|
EP3787694A4
(en)
|
2018-04-29 |
2022-05-18 |
University of Massachusetts |
RAAV-MEDIATED NUCLEASE-ASSOCIATED VECTOR INTEGRATION (RAAV-NAVI)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
JP7832761B2
(ja)
|
2018-06-08 |
2026-03-18 |
インテリア セラピューティクス，インコーポレイテッド |
遺伝子編集のための修飾されたガイドｒｎａ
|
|
WO2019239361A1
(en)
|
2018-06-14 |
2019-12-19 |
Novartis Ag |
Method for sequence insertion using crispr
|
|
GB2596224B
(en)
|
2018-06-19 |
2022-09-07 |
Univ Texas |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
EP3814499A2
(en)
|
2018-06-28 |
2021-05-05 |
CRISPR Therapeutics AG |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
|
WO2020032986A1
(en)
*
|
2018-08-10 |
2020-02-13 |
Logicbio Therapeutics, Inc. |
Non-disruptive gene therapy for the treatment of mma
|
|
IL326835A
(en)
|
2018-10-16 |
2026-04-01 |
Blueallele Llc |
Methods for targeted insertion of dna genes
|
|
BR112021007343A2
(pt)
|
2018-10-18 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para expressão de transgene a partir de um lócus de albumina
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
MX2021004276A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Composiciones y metodos para tratar deficiencia de alfa-1 antitripsina.
|
|
CN113272428A
(zh)
|
2018-10-18 |
2021-08-17 |
英特利亚治疗股份有限公司 |
核酸构建体和使用方法
|